"Designing Growth Strategies is in our DNA"

Cardiometabolic Disease Market Size, Share and Global Trend By Treatment (Angiotensin-converting Enzyme (ace) Inhibitors, Diuretics, Glucophage), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Geography Forecast till 2026

Region : Global | Report ID: FBI100207 | Status : Ongoing

 

KEY MARKET INSIGHTS

The Cardiometabolic Disease can be described as a combination of metabolic dysfunctions which is often characterized by a number of diseases such as impaired glucose tolerance, insulin resistance, hypertension, central adiposity, and dyslipidemia. Individuals diagnosed with the cardiometabolic disease are two times more susceptible and three times more susceptible to die by coronary heart disease and heart attack or stroke respectively.

It can be further stated that cardiovascular disease is one of the many forms of the cardiometabolic disease. One of the critical reasons for the anticipation growth of the market is a very high prevalence of cardiometabolic disease and the other associated comorbidities such as diabetes, obesity amongst others. Due to the increasing initiatives towards the research & development of new cardiometabolic therapeutics and the increasing rate of obesity is also expected to further contribute to market growth. 

To gain extensive insights into the market, Request for Customization

Cardiometabolic Disease and various associated comorbidities are amongst the most prevalent and common diseases globally due to a number of factors. Due to the increased awareness and the greater availability and access to cardiometabolic disease treatment options, some of the diseases are no longer fatal with efficient and appropriate treatment. This is further expected to contribute towards the growth of the market and the increased R&D for the new treatment options and the availability of the therapeutics in the emerging markets at subsidized prices are further expected to drive the market growth positively. 

The factor that is expected to inhibit the growth of the market is the adverse effects associated with cardiometabolic disease treatments. For instance, one of the most critical treatments for cardiometabolic diseases is the angiotensin-converting-enzyme (ACE) inhibitors, a group of drugs used for the treatment of heart failures and hypertension. But in some instances, the complications also include angioedema, a potentially fatal health condition. 

Key Players Covered 

Some of the major companies that are present in the global cardiometabolic disease market are Cardax, Inc., Novartis AG, Novo Nordisk A/S, Eli Lilly and Company, Bayer AG, Allergan, Boehringer Ingelheim International GmbH, AstraZeneca and other players. 

SEGMENTATION 

 SEGMENTATION

 DETAILS

By Treatment

·      Angiotensin-converting Enzyme (ace) Inhibitors

·      Diuretics

·      Glucophage

·      Others

By Distribution Channel

·      Hospital Pharmacies

·      Retail Pharmacies

·      Online Pharmacies

·      Others

By Geography

·      North America (USA and Canada)

·      Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

·      Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

·      Latin America (Brazil, Mexico and Rest of Latin America)

·      Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

                               

At present, ACE inhibitors account for the largest proportion of the market and this is expected to remain same during the forecast period because of the utilization of the treatment for the management of hypertension and heart failure. Also, there is a high prevalence of the disease in North America due to the high prevalence of comorbidities such as diabetes and obesity. 

Key Insights 

  • Pipeline analysis
  • Regulatory scenario by key countries
  • Overview of therapeutics currently approved for the cardiometabolic disease
  • Prevalence of cardiometabolic and cardiovascular disease by key countries
  • New product launches 

Regional Analysis 

The global cardiometabolic disease market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for the cardiometabolic disease at present and they are expected to account for a large proportion of the market in the forecast period as well. In the U.S., according to the American College of Cardiology (ACC), there are an estimated 47 million individuals who are diagnosed with some form of the cardiometabolic disease, which can lead to the progression towards atherosclerosis disease. In the Asia Pacific region, China is expected to provide the largest market opportunity. This is owing to the high prevalence of cardiometabolic and cardiovascular disease in China. 

Key Industry Developments

  • In March 2019, Alnylam Pharmaceuticals, Inc. announced that the company had submitted an application for the clinical trial authorization (CTA) to the U.K. regulatory authority for the initiation of a Phase 1 study for ALN-AGT, an investigational RNAi therapeutic for the targeting of angiotensinogen (AGT), for the treatment of hypertension and heart failure.
  • In March 2019, Arrow Pharmaceuticals Inc., began the dosing of the first subjects in its Phase 1 clinical study of ARO-APOC3, a RNAi-based investigational medicine for the targeting of apolipoprotein C-III (apoC-III), to be utilised for the treatment of hypertriglyceridemia.

Cardiometabolic Disease Market Size, Share and Global Industry Trend Forecast till 2026
  • Ongoing
  • 2019
  • 2016-2018

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization

Healthcare Clients

baxter
Sedana-Cyan-Black-Tag
Ge-Healthcare
Intuitive_Surgical_logo
Natus-Medical

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X